Posted by This second-generation delivery device provides a cost-efficient alternative to in-hospital treatment. Lasix® ONYU represents the most recent FDA-approved formulation incorporating betadex sulfobutyl ether sodium.
SQ Innovation Inc., has developed Lasix® ONYU (furosemide injection), a novel drug-device combination designed to treat edema caused by fluid overload in adults with chronic heart failure. The product enables subcutaneous administration outside the healthcare setting, as prescribed by a clinician, eliminating the need for a healthcare professional to administer the drug.
The product features a high-concentration furosemide formulation integrated with an advanced small infusor device, allowing patients to receive therapy at home. Its innovative system includes a reusable unit that lasts up to 48 treatments and a single-use sterile component discarded after each use.
Episodes of edema due to fluid overload are a leading cause of hospitalizations in heart failure patients—commonly treated with IV furosemide. Lasix® ONYU provides comparable diuretic efficacy to IV therapy but can be administered at home, offering a significant step toward reducing hospital admissions and healthcare costs. Approximately 6.7 million Americans are affected by heart failure, a number projected to reach 8.7 million by 2030, resulting in about 1.2 million hospitalizations annually.
Each 1 mL dose of Lasix® ONYU contains 30 mg of furosemide and the following inactive ingredients: betadex sulfobutyl ether sodium (300 mg), hydrochloric acid for pH adjustment if needed, sodium hydroxide for pH adjustment if needed, tromethamine (3 mg), and water for injection (q.s.).
SQ Innovation anticipates Lasix® ONYU will be available in Q4 2025. For important safety information and full prescribing details, visit: